Title : Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Pub. Date : 2022 Jan

PMID : 34763937






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. enzalutamide androgen receptor Homo sapiens
2 OBJECTIVES: We sought to determine the safety and efficacy of the oral androgen receptor antagonist enzalutamide in patients with previously treated, recurrent, AR-positive (AR+) ovarian cancer. enzalutamide androgen receptor Homo sapiens